ArticleEuropean journal of medical research2023
FVC/D
Article in European journal of medical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Unveiling MicroRNA-21 as a non-invasive diagnostic biomarker in chronic obstructive pulmonary disease-associated pulmonary hypertension: Comparative insights with NT-proBNP.Lung India : official organ of Indian Chest Society · 2026Article
- Prognostic models for mortality and hospitalisation risk in a contemporary Australian chronic obstructive pulmonary disease cohort.Respiratory research · 2026Article
- The Predictive Value of the Combined FVC/DLCO Ratio and 1-Minute Heart Rate Recovery After Exercise in Stable Chronic Obstructive Pulmonary Disease with Pulmonary Hypertension.International journal of general medicine · 2026Article
- The FEV1/DLCO Ratio as an Effective Predictor of Severity and Survival in COPD-Associated Pulmonary Hypertension: A Retrospective Analysis.Journal of clinical medicine · 2025Article
- Chest Computed Tomography to Improve Phenotyping in Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease.Annals of the American Thoracic Society · 2025Article
- Biomarkers in COPD-Associated PH/CCP: Circulating Molecules and Cell-Intrinsic Marker.International journal of chronic obstructive pulmonary disease · 2025Review
- Article
- Predictors of Mortality in Pulmonary Hypertension-Associated Chronic Lung Disease.Journal of clinical medicine · 2024Article
- Prediction of clinical risk assessment and survival in chronic obstructive pulmonary disease with pulmonary hypertension.Clinical and translational medicine · 2024Article
- Prevalence of pulmonary hypertension and its associated factors among chronic obstructive pulmonary diseases patients at public hospitals of Addis Ababa, Ethiopia, 2024: a facility-based cross-sectional study.Frontiers in public health · 2024Article
- Diagnostic value of combined FVC%/DLCO% and echocardiography in connective tissue disorder‑associated pulmonary hypertension.Medicine internationalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPulmonary hypertension (PH) is a common complication of chronic obstructive pulmonary disease (COPD). However, it is unknown whether the ratio of forced vital capacity (FVC) to diffusing lung capacity for carbon monoxide (D
methodsThe study population I included 937 COPD patients who were admitted to inpatient treatments from 2010 to 2017, and finally 750 patients were available to follow-up the 5-year all-cause mortality (study population II). Clinical characteristics of the study population were recorded.
resultsCOPD patients with PH had a higher FVC/D
conclusionFVC/D
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.